Integrated Treatment Approaches Dyslipidemia in Patients with Coronary Heart Disease

  • Tursunova Dilobar Erkinovna
Keywords: coronary heart disease, stable angina pectoris, blood lipids, plasmapheresis, ultraviolet blood irradiation

Abstract

The risk of developing coronary artery disease increases significantly with an increase in blood levels of cholesterol and low-density lipoprotein (LDL).

It is known that it is not always possible to achieve target levels of blood lipids in patients with coronary artery disease with standard therapy. We examined 100 patients with ischemic heart disease (IHD): stable angina II-III functional class - study group (60 patients) and comparison group (40 patients). As a result of research, we have obtained data that the combination of plasmapheresis, ultraviolet blood irradiation and statins can reduce the level of total cholesterol in patients with II FC by 2.7%, III FC by 23.3%, LDL levels in patients with II FC by 30 .4%, III FC by 37.3% (p<0.05). After complex therapy, the achieved level of lipidemia can be maintained by lower doses of statins.

References

1. Aronov, D.M. Primary and secondary prevention of cardiovascular diseases interpolation to Russia. D.M. Aronov. Heart 2002; 3:109-113.
2. Zhilyaeva Yu.A. Mikhin V.P., Zhilyaeva O.A. The state of parameters of blood lipid peroxidation and elastic properties of the vascular wall in patients with coronary heart disease during therapy with generic statins. Kursk. scientific-practical. vestn.≪Man and his health≫. 2013; 4:66-72.
3. Karpov Yu.A. Treatment of patients with stable angina pectoris: to the release of new recommendations of VNOK. Russian medical journal. 2008; 21:1379-1384.
4. National clinical guidelines. Collection. Under. ed. R.G. Oganov. 3rd edition. M.: Publishing house≪Silicea-Polygraph≫, 2010. 568.
5. A. M. Pristrom, S. V. Samokhodkina, and M. L. Kreiter, Russ. Comparative efficacy and safety of Mertenil (rosuvastatin) in patients with hyperlipidemia. Honey. news. 2013; 3:51–56.
6. Lablanche JM, Danchin N., Farnier M. et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch. Cardiovasc. Dis. 2008; 101:399–406.
7. Garcia Rodriguez LA, Herings R., Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological program comparing rosuvastatin with other marketed statins. Pharmacoepidemiol. drug safe. 2010; 19(12): 1218–1224.
8. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27(11): 1341-1381.
9. Kannel WB, Plehn JF, Cupples LA Cardiac failure and sudden death in the Framingham Study. Am. Heart J. 1988; 115(4): 869-875.
10. Linsel-Nitschke P., Samani NJ, Schunkert HN Sorting out cholesterol and coronary artery disease. English J. Med. 2010; 363:2462-2463.
11. Spagnoli LG, Bonanno E., Sangiorgi G., Mauriello A. Role of Inflammation in Atherosclerosis. J. Nucl. Med. 2007; 48: 1800–1815
Published
2022-11-30
How to Cite
Erkinovna, T. D. (2022). Integrated Treatment Approaches Dyslipidemia in Patients with Coronary Heart Disease. Central Asian Journal of Medical and Natural Science, 3(6), 270-273. https://doi.org/10.17605/cajmns.v3i6.1203
Section
Articles